Drug interactions
Dabrafenib + Regorafenib
Severity: Major
Dabrafenib and Regorafenib: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Dabrafenib induces CYP3A4 and can lower regorafenib exposure, possibly reducing anticancer efficacy while increasing the active metabolite M-5.
What this interaction means in plain words
Dabrafenib and Regorafenib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Dabrafenib belongs to Oncology; Regorafenib belongs to Oncology.
Why it happens
Dabrafenib induces CYP3A4, accelerating regorafenib clearance.
What to do
Avoid concomitant use of strong CYP3A4 inducers with regorafenib. If needed, monitor for loss of efficacy and toxicity.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Dabrafenib and Regorafenib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Regorafenib
Other interactions of Dabrafenib
Frequently asked questions
Can I take Dabrafenib with Regorafenib?
MediHelp rates the interaction as major. Dabrafenib and Regorafenib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Dabrafenib induces CYP3A4 and can lower regorafenib exposure, possibly reducing anticancer efficacy while increasing the active metabolite M-5.
How serious is the interaction between Dabrafenib and Regorafenib?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid concomitant use of strong CYP3A4 inducers with regorafenib. If needed, monitor for loss of efficacy and toxicity.
What other medicines interact with Regorafenib?
MediHelp also lists interactions of Regorafenib with, for example, Apalutamide, Atazanavir, Carbamazepine. The full list is on the Regorafenib page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
